Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 10/20 | 0.64 |
| ▸ | NSD2 | O96028 | 1/20 | 0.60 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.60 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.60 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.60 |
| ▸ | MARS1 | P56192 | 1/20 | 0.56 |
| ▸ | CCKAR | P32238 | 1/20 | 0.53 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.52 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.52 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16921447 | 0.89 | RPA1 (0.58) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL1765024 | 0.88 | PPP1CA (0.68) | RPA1NSD2NSD1NSD3LPAR5 | |
| SCHEMBL1765059 | 0.88 | MARS1 (0.59) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL1765042 | 0.88 | RPA1 (0.64) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL1765261 | 0.87 | FAAH (0.56) | RPA1NSD2NSD1NSD3LPAR5 | |
| SCHEMBL14995378 | 0.87 | RPA1 (0.66) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL1764965 | 0.86 | RPA1 (0.65) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL1765068 | 0.84 | PPP1CA (0.71) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL16921424 | 0.84 | RPA1 (0.59) | RPA1MARS1PPP1CAMEN1KMT2A | |
| SCHEMBL1764984 | 0.84 | RPA1 (0.63) | RPA1NSD2NSD1NSD3LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | RPA1 3978/4885NSD2 1679/4885NSD1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.